颈椎病诊断及治疗市场－全球产业规模、份额、趋势、机会及预测（按诊断、产品类型、通路、地区和竞争格局划分，2021-2031年）

全球颈椎病诊断和治疗市场预计将从 2025 年的 64.4 亿美元增长到 2031 年的 95.1 亿美元，复合年增长率为 6.71%。

此领域涵盖透过先进的影像技术和治疗性介入，对颈椎退化性病变进行医学识别和管理，以治疗椎间盘和关节退化。成长的主要驱动因素是全球人口快速老化以及生活方式因素导致的颈部疾病发病率上升，从而产生了对有效疼痛管理和復健护理的迫切需求。此外，早期发现以避免永久性神经损伤的重视也推动了市场扩张。根据全球肌肉骨骼健康联盟（Global Alliance for Musculoskeletal Health）2024年报告，颈痛影响全球约2.03亿人，由于人口结构变化，预计到2050年这一数字将达到2.69亿。

儘管市场前景广阔，但仍面临诸多挑战，包括先进诊断技术和外科手术的高成本，这限制了对成本敏感地区患者的就医途径。此外，开发中国家择期脊椎手术报销政策不足以及合格脊椎专科医生短缺，往往会进一步加剧此经济障碍。这些因素共同导致资源匮乏地区难以获得高品质的治疗方案，阻碍了市场渗透率的提高。

市场驱动因素

全球老年人口的快速增长和预期寿命的延长正在推动市场发展，直接导致易患退化性脊椎疾病的患者数量增加。随着老龄化，颈椎自然会磨损，导致椎间盘劣化和骨赘形成，这些都需要医疗干预。根据StatPearls Publishing于2025年5月发布的关于颈椎病的报告，该疾病被认为是老龄化的自然组成部分，65岁人群的患病率高达95%，预计治疗需求将保持稳定和持续增长。联合国于2024年7月发布的《2024年世界人口展望》报告进一步印证了这一趋势。该报告预测，到2024年，65岁及以上人口将达到8.3亿，到2054年将翻一番，达到17亿，这证实了患者群体规模的不断扩大。

同时，诊断影像和微创脊椎手术技术的进步提高了治疗的精准度和患者安全性，从而推动了市场成长。诸如机器人导航和先进的磁振造影技术等创新技术能够实现精准干预，与传统手术相比，显着降低了手术风险和缩短了恢復时间。这使得越来越多的患者选择接受以往被认为创伤过大的修復性手术。例如，2024年9月发表在《贝克尔脊椎评论》（Becker's Spine Review）上的报导指出，Globus Medical在第二季度的机器人设备安装量同比增长了59%。这些进步透过促进尖端高科技解决方案的应用，改善了患者的治疗效果，并推动了行业收入的成长。

市场挑战

先进的诊断技术和手术干预的高昂费用是颈椎病诊断和治疗市场发展的主要障碍。 MRI和CT扫描仪等影像设备以及脊椎移植和器械所需的大量资金，在价格敏感地区往往令人望而却步。这种经济负担将患者群体限制在拥有雄厚私人资金或广泛保险的个人，实际上将相当一部分需要治疗颈椎退化性疾病的人排除在外。因此，高端治疗方案主要集中在已开发经济体，而低收入市场则面临获得标准治疗的挑战。

医疗机构面临的经济挑战因不完善的报销政策而进一步加剧，这些政策无法充分补偿医疗服务提供者不断增长的营运成本。复杂手术报销额的降低使得医疗服务提供者难以维持先进的手术设施或投资新兴技术。据美国医学会称，2024年医疗保险医师费用表转换係数将降低3.37%，这将加重进行脊椎介入手术的医师的经济负担。这些报销额的降低阻碍了必要治疗方法的普及，并减少了愿意进行这些择期手术的专科医生数量，从而抑制了整个行业的成长。

市场趋势

随着外科医生越来越倾向于选择与传统光滑聚合物植入植入相比具有更优异骨整合性能的植入，业界正经历着从PEEK材质到3D列印钛合金颈椎融合器的重大转变。积层製造技术能够生产高度多孔的钛合金结构，模拟鬆质骨的结构，从而有助于在颈椎前路切除术切除融合术（ACDF）中早期实现生物固定和稳定性。这项技术进步正在改变製造商的产品系列，并为该领域带来显着的收入成长。例如，史赛克公司于2024年10月发布的「2024年第三季营运业绩」显示，整形外科和脊椎业务部门的净销售额成长了10.7%。这一业绩成长主要得益于市场对该公司先进的生物工程脊椎移植技术的持续需求。

同时，在支付方节约成本策略和微创技术日益精进的推动下，颈椎手术门诊手术中心（ASC）的兴起正在从根本上改变医疗服务的模式。随着颈椎减压和全人工椎间盘置换术效率的提高，患者数量正迅速从昂贵的住院治疗转向能够更快出院的专业门诊机构。这种结构性转变体现在这些机构高风险病例的激增。根据果冻 Partners 于 2024 年 11 月发布的“2024 年第三季度财报电话会议”，该公司旗下机构的全关节置换术和高危险关节置换术量同比增长超过 50%，表明门诊环境下复杂的整形外科和脊柱护理模式正被越来越多的人接受。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球颈椎病诊断与治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过诊断（影像检查、颈部X光片、MRI、CT造影、神经功能检查、肌电图、神经传导检查）
  • 依产品类型（药品、医疗设备、手术器材）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美颈椎病诊断与治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲颈椎病诊断与治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区颈椎病变诊断与治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲颈椎病诊断和治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲颈椎病诊断与治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球颈椎病变诊断与治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novartis AG
• Merck & Co. Inc.
• Bayer AG
• Abbott Laboratories Inc.
• Ortho Bracing
• Medtronic Plc
• Stryker Corporation
• B. Braun SE
• DJO, LLC
• Aspen Medical Products, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cervical Spondylosis Diagnosis And Treatment Market is projected to expand from USD 6.44 Billion in 2025 to USD 9.51 Billion by 2031, registering a CAGR of 6.71%. This sector encompasses the medical identification and management of degenerative cervical spine changes through advanced imaging and therapeutic interventions designed to treat disk and joint deterioration. Growth is largely propelled by a rapidly aging global population and a rising incidence of lifestyle-induced neck disorders, creating a strong need for effective pain management and restorative care. Additionally, the focus on early detection to avert permanent neurological damage reinforces market expansion. As reported by the Global Alliance for Musculoskeletal Health in 2024, neck pain affected approximately 203 million people worldwide, with this figure expected to reach 269 million by 2050 due to shifting demographics.

Despite promising growth prospects, the market faces significant hurdles due to the high costs of advanced diagnostic technologies and surgical procedures, which restrict access for patients in cost-sensitive areas. This financial obstacle is frequently compounded by insufficient reimbursement policies for elective spinal surgeries and a scarcity of qualified spine specialists in developing countries. These factors collectively limit the widespread adoption of premium treatment options, preventing broader market penetration in regions where healthcare resources are constrained.

Market Driver

The rapid growth of the global geriatric population and increasing life expectancy act as primary drivers for the market, directly elevating the number of patients prone to degenerative spinal issues. As people age, natural wear and tear on the cervical spine results in disk deterioration and osteophyte formation, requiring medical attention. According to a May 2025 report by StatPearls Publishing on 'Cervical Spondylosis,' the condition is viewed as a natural aging process with a 95% prevalence rate in individuals by age 65, ensuring steady demand for care. This trend is further supported by the United Nations' 'World Population Prospects 2024' report from July 2024, which noted that the global population aged 65 and older reached 830 million in 2024 and is expected to double to 1.7 billion by 2054, confirming the expanding scale of the patient base.

Concurrently, technological progress in diagnostic imaging and minimally invasive spinal surgeries is fueling market growth by improving treatment accuracy and patient safety. Innovations like robotic-assisted navigation and advanced MRI techniques enable precise interventions, which significantly lower surgical risks and recovery periods compared to conventional open surgeries, encouraging patients to choose restorative procedures previously considered too invasive. For example, an article in Becker's Spine Review from September 2024 titled 'Globus Medical's spine robot: 5 things to know' highlighted that Globus Medical saw a 59% year-over-year rise in robot unit placements during the second quarter. These advancements enhance patient outcomes and drive industry revenue by stimulating the adoption of premium, high-tech solutions.

Market Challenge

The high costs associated with advanced diagnostic technologies and surgical interventions represent a major obstacle to the growth of the cervical spondylosis diagnosis and treatment market. The substantial capital required for imaging equipment such as MRI and CT scanners, along with the expense of spinal implants and instrumentation, results in pricing that is often unaffordable in price-sensitive regions. This financial strain limits the patient base to individuals with considerable private funds or extensive insurance coverage, effectively excluding a significant demographic that needs treatment for degenerative neck conditions. As a result, the uptake of premium therapies is largely confined to developed economies, while lower-income markets encounter difficulties in accessing standard care.

This economic difficulty is exacerbated by inadequate reimbursement policies that do not sufficiently offset the rising operational expenses of medical practices. When compensation for complex procedures decreases, healthcare providers struggle to sustain advanced surgical facilities or invest in emerging technologies. According to the American Medical Association, the Medicare Physician Fee Schedule conversion factor was cut by 3.37 percent in 2024, intensifying the financial strain on physicians who perform spinal interventions. Such reimbursement reductions deter the widespread adoption of essential surgical solutions and reduce the number of specialists willing to undertake these elective procedures, thereby hindering the overall growth of the sector.

Market Trends

The industry is witnessing a significant shift from PEEK to 3D-Printed Titanium Cervical Cages, as surgeons increasingly favor implants that provide better osseointegration compared to traditional smooth polymers. Additive manufacturing allows for the production of highly porous titanium structures that replicate cancellous bone architecture, facilitating quicker biological fixation and stability during anterior cervical discectomy and fusion (ACDF) surgeries. This technological advancement is transforming manufacturer portfolios and generating substantial revenue growth in the segment. For instance, Stryker's 'Third Quarter 2024 Operating Results' from October 2024 revealed a 10.7% increase in net sales within their Orthopaedics and Spine segment, a performance attributed to the persistent demand for their advanced bio-engineered spinal implant technologies.

Simultaneously, the rise of Ambulatory Surgical Centers (ASCs) for cervical procedures is fundamentally changing the site-of-care landscape, influenced by payer cost-reduction strategies and the refinement of minimally invasive techniques. As cervical decompression and disc replacement surgeries become more efficient, patient volume is rapidly moving from expensive inpatient hospital departments to specialized outpatient facilities that provide faster discharge. This structural transition is evidenced by the surge in high-acuity cases within these settings. According to the 'Third Quarter 2024 Earnings Call' by Surgery Partners in November 2024, case volumes for total joint and high-acuity replacements in their facilities grew by over 50% year-over-year, underscoring the increasing acceptance of complex orthopedic and spinal care models in the ambulatory environment.

Key Market Players

• Novartis AG
• Merck & Co. Inc.
• Bayer AG
• Abbott Laboratories Inc.
• Ortho Bracing
• Medtronic Plc
• Stryker Corporation
• B. Braun SE
• DJO, LLC
• Aspen Medical Products, LLC

Report Scope

In this report, the Global Cervical Spondylosis Diagnosis And Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cervical Spondylosis Diagnosis And Treatment Market, By Diagnosis

• Imaging Tests
• Neck X-ray
• MRI
• CT Myelography
• Nerve Function Tests
• Electromyography
• Nerve Conduction Study

Cervical Spondylosis Diagnosis And Treatment Market, By Product Type

• Medications
• Medical Devices
• Surgical Instruments

Cervical Spondylosis Diagnosis And Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Cervical Spondylosis Diagnosis And Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cervical Spondylosis Diagnosis And Treatment Market.

Available Customizations:

Global Cervical Spondylosis Diagnosis And Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cervical Spondylosis Diagnosis And Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Imaging Tests, Neck X-ray, MRI, CT Myelography, Nerve Function Tests, Electromyography, Nerve Conduction Study)
  • 5.2.2. By Product Type (Medications, Medical Devices, Surgical Instruments)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cervical Spondylosis Diagnosis And Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Product Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Cervical Spondylosis Diagnosis And Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Product Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Product Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Product Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Cervical Spondylosis Diagnosis And Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Product Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Cervical Spondylosis Diagnosis And Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Product Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Distribution Channel

10. South America Cervical Spondylosis Diagnosis And Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Product Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Cervical Spondylosis Diagnosis And Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cervical Spondylosis Diagnosis And Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co. Inc.
• 15.3. Bayer AG
• 15.4. Abbott Laboratories Inc.
• 15.5. Ortho Bracing
• 15.6. Medtronic Plc
• 15.7. Stryker Corporation
• 15.8. B. Braun SE
• 15.9. DJO, LLC
• 15.10. Aspen Medical Products, LLC

16. Strategic Recommendations

17. About Us & Disclaimer